Toll-like receptor 4 and hepatitis B infection: Molecular mechanisms and pathogenesis

Viral Immunology

Volumn 27, Issue 7, 2014, Pages 321-326

  Zare Bidaki, Mohammad ^a   Tsukiyama Kohara, Kyoko ^b   Kazemi Arababadi, Mohammad ^a  

^a RAFSANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPOLYSACCHARIDE; MYELOID DIFFERENTIATION FACTOR 88; PATTERN RECOGNITION RECEPTOR; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TRANSCRIPTION FACTOR; TLR4 PROTEIN, HUMAN;

HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MOLECULAR BIOLOGY; NONHUMAN; PATHOGENESIS; REVIEW; SIGNAL TRANSDUCTION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY;

GENE EXPRESSION REGULATION; HEPATITIS B; HUMANS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4;

EID: 84907026830     PISSN: 08828245     EISSN: 15578976     Source Type: Journal    
DOI: 10.1089/vim.2014.0039     Document Type: Review

References (67)

1. Ahmadabadi BN, Hassanshahi G, Arababadi MK, et al. The IL-10 promoter polymorphism at position-592 is correlated with susceptibility to occult HBV infection. Inflammation 2012;35:818-821.
2. Alderson MR, McGowan P, Baldridge JR, and Probst P. TLR4 agonists as immunomodulatory agents. J Endotoxin Res 2006;12:313-319.
3. Aoyama T, Paik Y-H, and Seki E. Toll-like receptor signaling and liver fibrosis. Gastroenterol Res Pract 2010; 2010. doi:10.1155/2010/192543.
4. Arababadi MK, Ahmadabadi BN, and Kennedy D. Current information on the immunological status of occult hepatitis B infection. Transfusion 2012;52:1819-1826.
5. Arababadi MK, Pourfathollah AA, Jafarzadeh A, et al. Association of exon 9 but not intron 8 VDR polymorphisms with occult HBV infection in south-eastern Iranian patients. J Gastroenterol Hepatol 2009;25:90-93.
6. Arababadi MK, Pourfathollah AA, Jafarzadeh AA, and Hassanshahi G. Serum levels of Interleukin (IL)-10 and IL-17A in occult HBV infected south-east Iranian patients. Hepat Mon 2010;10:31-35.
7. Assar S, Arababadi MK, Ahmadabadi BN, et al. Occult hepatitis B virus (HBV) infection: a global challenge for medicine. Clin Lab 2012;58:1225-1230.
8. Ayoobi F, Hassanshahi G, Zainodini N, et al. Reduced expression of TRIF in chronic HBV infected Iranian patients. Clin Res Hepatol Gastroenterol 2013;37:491-495.
9. Bae YS, Lee JH, Choi SH, et al. Macrophages generate reactive oxygen species in response to minimally oxidized low-density lipoprotein: toll-like receptor 4-and spleen tyrosine kinase-dependent activation of NADPH oxidase 2. Circ Res 2009;104:210-218, 221p following 218.
10. Bhattacharyya S, Kelley K, Melichian D, et al. Toll-like receptor 4 signaling augments transforming growth factor-b responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma. Am J Pathol 2013;182:192-205.
11. Cario E, Gerken G, and Podolsky D. Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function. Gastroenterology 2007;132:1359-1374.
12. Chan HL, and Jia J. Chronic hepatitis B in Asia-new insights from the past decade. J Gastroenterol Hepatol 2011;26 Suppl 1:131-137.
13. Chang W-W, Su I-J, Lai M-D, et al. Toll-like receptor 4 plays an anti-HBV role in a murine model of acute hepatitis B virus expression. World J Gastroenterol 2005;11:6631.
14. ChangWW, Su IJ, Lai MD, et al. The role of inducible nitric oxide synthase in a murine acute hepatitis B virus (HBV) infection model induced by hydrodynamics-based in vivo transfection of HBV-DNA. J Hepatol 2003;39:834-842.
15. Chen Z, Cheng Y, Xu Y, et al. Expression profiles and function of Toll-like receptors 2 and 4 in peripheral blood mononuclear cells of chronic hepatitis B patients. Clin Immunol 2008;128:400-408.
16. Cheng X, and Zhang L. [The significance of CD14 and TLR4 expressions in severe hepatitis B induced by endotoxin]. Zhonghua Gan Zang Bing Za Zhi 2010;18:428.
17. Chizzolini C, Brembilla NC, Montanari E, and Truchetet M-E. Fibrosis and immune dysregulation in systemic sclerosis. Autoimmun Rev 2011;10:276-281.
18. Curtale G, Mirolo M, Renzi TA, et al. Negative regulation of Toll-like receptor 4 signaling by IL-10-dependent microRNA-146b. Proc Nat Acad Sci 2013;110:11499-11504.
19. Cussigh A, Fabris C, Fattovich G, et al. Toll like receptor 4 D299G associates with disease progression in Caucasian patients with chronic HBV infection: relationship with gender. J Clin Immunol 2013;33:313-316.
20. Erridge C. Endogenous ligands of TLR2 and TLR4: agonists or assistants? J Leukoc Biol. 2010;87:989-999.
21. Evans JT, Cluff CW, Johnson DA, et al. Enhancement of antigen-specific immunity via the TLR4 ligands MPL-adjuvant and Ribi. 529. Expert Rev Vaccines 2003;2:219-229.
22. Fitzgerald KA, Rowe DC, Barnes BJ, et al. LPS-TLR4 signaling to IRF-3/7 and NF-jB involves the toll adapters TRAM and TRIF. J Exp Med 2003;198:1043-1055.
23. Heiberg IL, Winther TN, Paludan SR, and Hogh B. Pattern recognition receptor responses in children with chronic hepatitis B virus infection. J Clin Virol 2012;54:229-234.
24. Hirayama T, Tamaki Y, Takakubo Y, et al. Toll-like receptors and their adaptors are regulated in macrophages after phagocytosis of lipopolysaccharide- coated titanium particles. J Orthop Res 2011;29:984-992.
25. Imani Fooladi AA, SF Mousavi, S Seghatoleslami, et al. Toll-like receptors: role of inflammation and commensal bacteria. Inflamm Allergy Drug Targets 2011;10:198-207.
26. Isogawa M, Robek MD, Furuichi Y, and Chisari FV. Tolllike receptor signaling inhibits hepatitis B virus replication in vivo. J Virol 2005;79:7269-7272.
27. Jia N, Xie Q, Lin L, et al. Common variants of the TLR9 gene influence the clinical course of HBV infection. Mol Med Report 2009;2:277-281.
28. John B, and Crispe IN. TLR-4 regulates CD8 + T cell trapping in the liver. J Immunol 2005;175:1643-1650.
29. Kagan JC, and Medzhitov R. Phosphoinositide-mediated adaptor recruitment controls Toll-like receptor signaling. Cell 2006;125:943-955.
30. Kawai T, and Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011;34:637-650.
31. Khorramdelazad H, Hassanshahi G, Ahmadabadi BN, and Arababadi MK. High serum levels of TGF-b in Iranians with chronic HBV infection. Hepat Mon 2012;12:e7581.
32. Khvalevsky E, Rivkin L, Rachmilewitz J, et al. TLR3 signaling in a hepatoma cell line is skewed towards apoptosis. J Cell Biochem 2007;100:1301-1312.
33. Lang T, Lo C, Skinner N, et al. The hepatitis B e antigen (HBeAg) targets and suppresses activation of the toll-like receptor signaling pathway. J Hepatol 2011;55:762-769.
34. Lian JQ, Wang XQ, Zhang Y, et al. Correlation of circulating TLR2/4 expression with CD3 +/4 +/8 + T cells and Treg cells in HBV-related liver cirrhosis. Viral Immunol 2009;22:301-308.
35. Liang B, Chen R, Wang T, et al. Myeloid differentiation factor 88 promotes growth and metastasis of human hepatocellular carcinoma. Clin Cancer Res 2013;19:2905-2916.
36. Lippai D, Bala S, Csak T, et al. Chronic alcohol-induced microRNA-155 contributes to neuroinflammation in a TLR4-dependent manner in mice. PloS One 2013;8:e70945.
37. Lu Y-C, Yeh W-C, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine 2008;42:145-151.
38. Maeda S. NF-jB, JNK, and TLR signaling pathways in hepatocarcinogenesis. Gastroenterol Res Pract 2010;2010: 367694.
39. Matsuzaki K, Murata M, Yoshida K, et al. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor b signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology 2007;46:48-57.
40. Mendy ME, Welzel T, Lesi OA, et al. Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in The Gambia, West Africa. J Viral Hepat 2009;27:27.
41. Michielsen P, and Ho E. Viral hepatitis B and hepatocellular carcinoma. Acta Gastroenterol Belg 2011;74:4-8.
42. Nguyen-Pham TN, Lim MS, Nguyen TA, et al. Type I and II interferons enhance dendritic cell maturation and migration capacity by regulating CD38 and CD74 that have synergistic effects with TLR agonists. Cell Mol Immunol 2011;8:341-347.
43. Pan C, Gu Y, Zhang W, et al. Dynamic changes of lipopolysaccharide levels in different phases of acute on chronic hepatitis B liver failure. PloS One 2012;7:e49460.
44. Philippe L, Alsaleh G, Pichot A, et al. MiR-20a regulates ASK1 expression and TLR4-dependent cytokine release in rheumatoid fibroblast-like synoviocytes. Ann Rheum Dis 2013;72:1071-1079.
45. Qureshi ST, Larivière L, Leveque G, et al. Endotoxintolerant mice have mutations in Toll-like receptor 4 (Tlr4). J Exp Med 1999;189:615-625.
46. Sajadi SMA, Mirzaei V, Hassanshahi G, et al. Decreased expressions of TLR9 and its signalingmolecules in chronicHBV infected patients. Arch Path Lab Med. 2013;137:1674-1679.
47. Schwabe RF, Seki E, and Brenner DA. Toll-like receptor signaling in the liver. Gastroenterology 2006;130:1886-1900.
48. Shahid SM, Fatima SN, and Mahboob T. Angiotensin converting enzyme (ACE) gene expression in experimentally induced liver cirrhosis in rats. Pak J Pharm Sci 2013;26:853-857.
49. Shi B, Ren G, Hu Y, et al. HBsAg inhibits IFN-alpha production in plasmacytoid dendritic cells through TNFalpha and IL-10 induction in monocytes. PLoS One. 2012; 7:e44900.
50. Shirai Y, Yoshiji H, Noguchi R, et al. Cross talk between toll-like receptor-4 signaling and angiotensin-II in liver fibrosis development in the rat model of non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2013;28:723-730.
51. Soares J-B, Pimentel-Nunes P, Afonso L, et al. Increased hepatic expression of TLR2 and TLR4 in the hepatic inflammation-fibrosis-carcinoma sequence. Innate Immun 2012;18:700-708.
52. Tarao K, Ohkawa S, Miyagi Y, et al. Inflammation in background cirrhosis evokes malignant progression in HCC development from HCV-associated liver cirrhosis. Scand J Gastroenterol 2013;48:729-735.
53. Visvanathan K, Skinner NA, Thompson AJ, et al. Regulation of toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology 2007;45:102-110.
54. Wang F-P, Li L, Li J, et al. High mobility group box-1 promotes the proliferation and migration of hepatic stellate cells via TLR4-dependent signal pathways of PI3K/Akt and JNK. PloS One 2013;8:e64373.
55. Wang S, Chen Z, Hu C, et al. Hepatitis B virus surface antigen selectively inhibits TLR2 ligand-induced IL-12 production in monocytes/macrophages by interfering with JNK activation. J Immunol 2013;190:5142-5151.
56. Wang X, Zhou Y, Zhu N, and Yuan W-J. Effects of hepatitis B virus X gene on apoptosis and expression of immune molecules of human proximal tubular epithelial cells. Arch Virol 2013;158:2479-2485.
57. Wei XQ, Guo YW, Liu JJ, et al. The significance of tolllike receptor 4 (TLR4) expression in patients with chronic hepatitis B. Clin Invest Med 2008;31:E123-130.
58. Wilson R, Warner N, Ryan K, et al. The hepatitis B e antigen suppresses IL-1beta-mediated NF-kappaB activation in hepatocytes. J Viral Hepat 2011;18:e499-507.
59. Wu J-F, Chen C-H, Ni Y-H, et al. Toll-like receptor and hepatitis B virus clearance in chronic infected patients: a long-term prospective cohort study in Taiwan. J Infect Dis 2012;206:662-668.
60. Wu J, Lu M, Meng Z, et al. Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology 2007;46:1769-1778.
61. Wu J, Meng Z, Jiang M, et al. Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology 2009;49:1132-1140.
62. Xing T, Li L, Cao H, and Huang J. Altered immune function of monocytes in different stages of patients with acute on chronic liver failure. Clin Exp Immunol 2007;147: 184-188.
63. Yamamoto M, Sato S, Hemmi H, et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 2003;301:640-643.
64. Zare-Bidaki M, Hakimi H, Abdollahi SH, et al. TLR4 in toxoplasmosis; friends or foe? Microb Pathog 2014;69-70:28-32.
65. Zhang Y, Lian JQ, Huang CX, et al. Overexpression of tolllike receptor 2/4 on monocytes modulates the activities of CD4(+)CD25(+) regulatory T cells in chronic hepatitis B virus infection. Virology 2010;397:34-42.
66. Zhou L, Wei B, Xing C, et al. Polymorphism in 3¢-untranslated region of toll-like receptor 4 gene is associated with protection from hepatitis B virus recurrence after liver transplantation. Transpl Infect Dis 2011;13:250-258.
67. Zhou Y, Zhu N, Wang X, et al. The role of the toll-like receptor TLR4 in hepatitis B virus-associated glomerulonephritis. Arch Virol 2013;158:425-433.